Since GlaxoSmithKline 's (GSK) full-year results in February, we've had management changes, strategy shifts and clinical updates galore.
IC TIP:
Sell
at
1658p
Financially, things have also been looking up after first-quarter results came in ahead of expectations. But GSK's reliance on the low-margin consumer healthcare division remains a concern. The big question in terms of our sell advice on this income stock will be whether there is any improvement in cash flow when the group announces interims next week.